SEC Comment Letter 0000000000-24-010954 to Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc.
Date: Sept. 26, 2024 · CIK: 0001636282 · Accession: 0000000000-24-010954
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282252
Letter
September 26, 2024 Cameron Turtle Chief Executive Officer Spyre Therapeutics, Inc. 221 Crescent Street, Bldg 23, Suite 105 Waltham, MA 02453 Re:Spyre Therapeutics, Inc. Registration Statement on Form S-3 Filed September 20, 2024 File No. 333-282252 Dear Cameron Turtle: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Branden C. Berns, Esq.
Show Raw Text
September 26, 2024
Cameron Turtle
Chief Executive Officer
Spyre Therapeutics, Inc.
221 Crescent Street, Bldg 23, Suite 105
Waltham, MA 02453
Re:Spyre Therapeutics, Inc.
Registration Statement on Form S-3
Filed September 20, 2024
File No. 333-282252
Dear Cameron Turtle:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Branden C. Berns, Esq.